Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.60 |
| ▸ | RXRA | P19793 | 5/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | EDNRA | P25101 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | DRD1 | P21728 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26193892 | 0.89 | RXRA (0.46) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac Sulfoxide SCHEMBL11255653 | 0.88 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL7939975 | 0.88 | PPARG (0.64) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL7942577 | 0.88 | PPARG (0.64) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL7942573 | 0.88 | PPARG (0.64) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL2029754 | 0.88 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL7939976 | 0.88 | PPARG (0.64) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL6881443 | 0.88 | PPARG (0.64) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL4202 | 0.88 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL6903607 | 0.88 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016799-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | MEDICON PHARMACEUTICALS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240016799-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | MEDICON PHARMACEUTICALS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11752146-B2 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | MEDICON PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11752146-B2 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | MEDICON PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20220162171-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS | Cellix Bio Provate Limited (IN) | 2022-05-26 | — | — | US | disclosed |
| US-11225464-B2 | Compositions and methods for the treatment of gastrointestinal polyps | CELLIX BIO PRIVATE LIMITED (IN) | 2022-01-18 | — | — | US | disclosed |
| US-20200246330-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | MEDICON PHARMACEUTICALS, INC. (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200190040-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS | CELLIX BIO PRIVATE LIMITED (IN) | 2020-06-18 | — | — | US | disclosed |
| US-20190343848-A1 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS | MEDICON PHARMACEUTICALS, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| US-8802726-B2 | Use of nitrooxyderivative of drug for the treatment of muscular dystrophies | NICOX S.A. (FR) | 2014-08-12 | — | — | US | disclosed |
| US-8575222-B2 | Use of nitrooxyderivatives of drug for the treatment of muscular dystrophies | NICOX S.A. (FR) | 2013-11-05 | — | — | US | disclosed |
| US-20130137765-A1 | USE OF NITROOXYDERIVATIVE OF DRUG FOR THE TREATMENT OF MUSCULAR DYSTROPHIES | NICOX S.A. (FR) | 2013-05-30 | — | — | US | disclosed |
| US-20090093510-A1 | Use of Nitrooxyderivatives of Drug for the Treatment of Muscular Dystrophies | NICOX SA (FR) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225464-B2 | Compositions and methods for the treatment of gastrointestinal polyps | APC, LPXN, SCNN1G | PPARG 805/4885RXRA 762/4885CYP1A2 729/4885 |
| US-20190343848-A1 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS | PDE6C, PDE6H, PDE6D | PPARG 961/4885RXRA 1157/4885CYP1A2 2250/4885 |
| US-20200246330-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | VEGFA, HPGDS, ALOX5 | PPARG 192/4885RXRA 1440/4885CYP1A2 836/4885 |
| US-20200190040-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS | APC, LPXN, SCNN1G | PPARG 805/4885RXRA 762/4885CYP1A2 729/4885 |
| US-20220162171-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS | APC, LPXN, SCNN1G | PPARG 805/4885RXRA 762/4885CYP1A2 729/4885 |
| US-11752146-B2 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | VEGFA, HPGDS, ALOX5 | PPARG 192/4885RXRA 1440/4885CYP1A2 836/4885 |
| US-20240016799-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | VEGFA, HPGDS, ALOX5 | PPARG 192/4885RXRA 1440/4885CYP1A2 836/4885 |
| US-20090093510-A1 | Use of Nitrooxyderivatives of Drug for the Treatment of Muscular Dystrophies | TNNC1, CPT1B, SMN1; SMN2 | PPARG 904/4885RXRA 1655/4885CYP1A2 1157/4885 |
| US-20130137765-A1 | USE OF NITROOXYDERIVATIVE OF DRUG FOR THE TREATMENT OF MUSCULAR DYSTROPHIES | TNNC1, CPT1B, SMN1; SMN2 | PPARG 1201/4885RXRA 1993/4885CYP1A2 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.